BridgeBio Pharma, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
BridgeBio Pharma, Inc. (BBIO) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-02-20
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.50%.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.20%.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.70%.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was -0.50%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2024-12-31 | -0.50% 10-K · filed 2025-02-20 |
| 2023-12-31 | -0.20% 10-K · filed 2025-02-20 |
| 2022-12-31 | -0.70% 10-K · filed 2025-02-20 |
| 2021-12-31 | -0.50% 10-K · filed 2024-02-22 |
| 2020-12-31 | -0.30% 10-K · filed 2023-02-23 |
| 2019-12-31 | -0.10% 10-K · filed 2022-02-25 |
| 2018-12-31 | -1.20% 10-K · filed 2021-02-25 |
| 2017-12-31 | -1.40% 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |